Rich Ericson C. King

Rich Ericson C. King

Auto-generated profile, based on publicly available information

Rich Ericson C. King

Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Current Problems in Cancer
Verified
Journal Article
Closed access
AAAnisah Hayaminnah Alonto
Anisah Hayaminnah Alonto
MMMark Willy L. Mondia
Mark Willy L. Mondia
CPCyril Jonas M. Planilla
Cyril Jonas M. Planilla
MMMarvin Jonne Mendoza
Marvin Jonne Mendoza
SUSheen C. Urquiza
Sheen C. Urquiza
MBMarjorie Anne C. Bagnas
Marjorie Anne C. Bagnas

27 June 2022 in Asian Journal of Oncology
Verified
Journal Article
Open access
PDF file
RKRich Ericson C. King
Rich Ericson C. King
KOKimberly Mae C. Ong
Kimberly Mae C. Ong
Background Cisplatin is a commonly used chemotherapeutic drug that is associated with irreversible hearing loss. A number of antioxidants have been investigated for prevention, but data have so far been inconclusive. Objective The objective of this study was to assess the efficacy of various antioxidant therapies in preventing hearing loss among adult patients treated with cisplatin. Methodology We searched for controlled clinical trials evaluating various antioxidants as prevention against cisplatin-induced hearing loss in adults. The primary outcome is the proportion of patients with hearing loss. Secondary outcomes include audiometric threshold shifts, tinnitus, tumor response, adverse events, and quality of life. Results Thirteen randomized trials comprising of nine antioxidant therapies were included. Only coenzyme Q with multivitamins demonstrated significant benefit in preventing cisplatin-induced hearing loss (relative risk: 0.15, 95% confidence interval: 0.04–0.58) in a small study, while data for the rest of the agents were inconclusive. Audiometric threshold shifts were significantly lower in the intervention arm for aspirin, vitamin E, and transtympanic dexamethasone. The available data on tumor response was inconclusive, with no definite evidence of diminished tumor response noted. Adverse events noted include mild ear pain particularly for transtympanic therapies. There was no data available on quality of life. Conclusion The current available evidence is so far insufficient to establish any benefit for antioxidant therapies for the prevention of cisplatin-induced hearing loss. More high-quality studies are needed to fill in the identified gaps in knowledge.

1 January 2020 in Journal of Medical Cases
Verified
Journal Article
Open access
PDF file
RKRich Ericson C. King
Rich Ericson C. King
AVAndrea R. Villaruel
Andrea R. Villaruel
JMJose Pedrito M. Magno
Jose Pedrito M. Magno
SGSean Patrick C. de Guzman
Sean Patrick C. de Guzman
LCLance Isidore G. Catedral
Lance Isidore G. Catedral
GFGracieux Y. Fernando
Gracieux Y. Fernando
Follicular dendritic cell sarcoma (FDCS) accounts for < 0.4% of soft tissue sarcomas. Only 35 cases of tonsillar FDCS have been reported, and majority had localized presentation. We present a case of FDCS of the tonsil, wherein a well-coordinated trimodality approach provided good disease control in advanced disease. A 53-year-old man presented with a painless and enlarging neck mass of 11-month duration, with no other symptoms. Close examination revealed a 10 × 5 cm mass at the left carotid triangle, and a 3.2 × 2.2 cm mass at the left tonsillar fossa. Imaging revealed the tumor to be unresectable due to its attachment to the great vessels. There were no distant metastases. Biopsy and immunohistochemistry were initially deemed consistent with an undifferentiated sarcoma. Palliative chemotherapy was given using single agent doxorubicin and subsequent dacarbazine, resulting in partial response and stable disease, respectively. Pathological re-evaluation was pursued because of the uncharacteristic slow progression of the tumor, revealing diffuse positivity for CD21 and negative for CD1A and CD34, consistent with FDCS. The patient underwent three cycles of gemcitabine plus docetaxel resulting in 50% regression. This allowed dissection of level IB-V lymph nodes and subsequent radiotherapy for the neck and tonsillar mass, with weekly gemcitabine as a radiosensitizer. Evaluation 8 months post-treatment showed no signs of disease progression. Treatment-related complications included radiation dermatitis and swallowing dysfunction, which both resolved on follow-up. This case highlights the multidisciplinary management of a rare type of sarcoma in an uncommon anatomic location. Precise pathologic diagnosis is important in soft tissue sarcoma because of its therapeutic implications. For FDCS, effective response may still be achieved in the third-line setting. J Med Cases. 2020;11(10):309-316 doi: https://doi.org/10.14740/jmc3551

25 November 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
RKR.E. King
R.E. King
DSDennis Sacdalan
Dennis Sacdalan
RAR.R. Angeles
R.R. Angeles
Background: The use of herbal products and dietary supplements (HDS) seem to be common among Filipinos. Among patients living with cancer, this is an important concern due to potential adverse effects and harmful interactions with conventional systemic therapy. Unfortunately, data is lacking regarding the prevalence and patterns of HDS use in this population.

30 May 2026 in Acta Medica Philippina
Verified
Journal Article
Open access
PDF file
MOMd Evelyn Osio-Salido
Md Evelyn Osio-Salido
NMNenacia Ranali Nirena P. Mendoza
Nenacia Ranali Nirena P. Mendoza
MRMd Bernadette Heizel M. Reyes
Md Bernadette Heizel M. Reyes
NJNathaniel S. Orillaza Jr.
Nathaniel S. Orillaza Jr.
MLMd Carl Froilan D. Leochico
Md Carl Froilan D. Leochico
ISIsabel Teresa Salido
Isabel Teresa Salido
Background and Objective. Musculoskeletal diseases (MSDs) are acutely or chronically painful conditions that cause limitations in mobility, dexterity, and participation in society. They are a major contributor to years lived with disability worldwide and their burden is higher in countries with a lower sociodemographic index, like the Philippines. The goal of this clinical practice guideline (CPG) is to provide recommendations to primary care providers on screening for MSDs among asymptomatic, apparently healthy children and adults. Methods. Following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to CPG development recommended in the Department of Health Manual, the evidence of net benefit or harm of screening for nine musculoskeletal conditions and risk factors was obtained through systematic literature search. Information on cost-effectiveness, patient values and preferences, acceptability, feasibility of screening, and its impact on equity were also obtained. The final recommendations were formulated through consensus by a panel of representatives from multiple stakeholder groups. Results. There were 15 recommendations formulated. Strong recommendations were given to screen for physical inactivity among adults, fall risks and sarcopenia for adults aged ≥60 years old, and osteoporosis among women aged ≥65 years old. However, strong recommendations were made against screening for low vitamin D among infants, children, and adults, and against screening for osteoporosis among men and among women aged <65 years old. Conclusion. Through a comprehensive evaluation of the best available evidence using the GRADE approach, the Task Force developed 15 recommendations on screening and risk factor assessment for nine MSDs. These recommendations will serve as guidance on screening for MSDs at the primary care level.

15 September 2026 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RKRich C. King
Rich C. King
ETErica Tsang
Erica Tsang
JKJennifer J Knox
Jennifer J Knox